Carla L. Alves

Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer

Carla L. Alves, Sidse Ehmsen, Mikkel G. Terp et al. · Nature Communications · 2021 · 84 citations · Full text

Medicine, Oncology, Pharmacology +17

Co-targeting CDK2 and CDK4/6 overcomes resistance to aromatase and CDK4/6 inhibitors in ER+ breast cancer

Abeer J. Al-Qasem, Carla L. Alves, Sidse Ehmsen et al. · npj Precision Oncology · 2022 · 78 citations · Full text

Medicine, Oncology, Pharmacology +17

High CDK6 Protects Cells from Fulvestrant-Mediated Apoptosis and is a Predictor of Resistance to Fulvestrant in Estrogen Receptor–Positive Metastatic Breast Cancer

Carla L. Alves, Daniel Eliáš, Maria Lyng et al. · Clinical Cancer Research · 2016 · 76 citations

Medicine, Oncology, Pharmacology +17

SNAI2 upregulation is associated with an aggressive phenotype in fulvestrant-resistant breast cancer cells and is an indicator of poor response to endocrine therapy in estrogen receptor-positive metastatic breast cancer

Carla L. Alves, Daniel Eliáš, Maria Lyng et al. · Breast Cancer Research · 2018 · 44 citations · Full text

Medicine, Molecular Biology, Oncology +17

Distinct mechanisms of resistance to fulvestrant treatment dictate level of ER independence and selective response to CDK inhibitors in metastatic breast cancer

Kamila Kaminska, Nina Akrap, Johan Staaf et al. · Breast Cancer Research · 2021 · 42 citations · Full text

Medicine, Oncology, Pharmacology +17